FindTrial
Sign In

Placebo to Adalimumab

DRUG4 trials

Sponsors

Hoffmann-La Roche, AbbVie (prior sponsor, Abbott), AbbVie

Conditions

Plaque PsoriasisPsoriatic ArthritisRheumatoid Arthritis

Phase 3

A Double Blind Study in Pediatric Subjects With Chronic Plaque Psoriasis, Studying Adalimumab vs. Methotrexate
CompletedNCT01251614
AbbVie (prior sponsor, Abbott)Plaque Psoriasis
Start: 2010-12-31End: 2015-02-28Updated: 2017-09-25
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)
CompletedNCT03104400
AbbViePsoriatic Arthritis
Start: 2017-04-27End: 2024-09-09Updated: 2025-09-22

Phase 4

A Study of Tocilizumab (RoActemra/Actemra) Versus Adalimumab in Patients With Rheumatoid Arthritis
CompletedNCT01119859
Hoffmann-La RocheRheumatoid Arthritis
Start: 2010-05-31End: 2012-01-31Updated: 2013-02-11
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor
TerminatedNCT01283971
Hoffmann-La RocheRheumatoid Arthritis
Start: 2011-05-31End: 2012-08-31Updated: 2014-02-10

Related Papers

Safety Profile of Upadacitinib: Descriptive Analysis in Over 27,000 Patient-Years Across Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Atopic Dermatitis, and Inflammatory Bowel Disease.
2025-08-282 citations
Effects of upadacitinib on enthesitis in patients with psoriatic arthritis: a post hoc analysis of SELECT-PsA 1 and 2 trials.
2024-11-017 citations
Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials
Rheumatology and Therapy2024-04-299 citations
Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis
Rheumatology and Therapy2023-11-2020 citations
MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
RMD Open2023-11-0123 citations
Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies.
2023-04-1010 citations
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis
RMD Open2023-02-01180 citations
Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study
Rheumatology and Therapy2022-10-1542 citations
Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials
Rheumatology and Therapy2022-05-233 citations
OA38 Efficacy and safety of upadacitinib in patients with psoriatic arthritis and axial involvement
Lara D. Veeken2022-04-23
Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials.
2021-12-3026 citations
Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis
Lara D. Veeken2021-11-3021 citations
Patient-Reported Outcomes in Psoriatic Arthritis Patients with an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: SELECT-PsA 2.
2021-10-1811 citations
Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1
Rheumatology and Therapy2021-10-1224 citations
Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study
Rheumatology and Therapy2021-04-2873 citations
Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis
New England Journal of Medicine2021-03-31276 citations
Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2.
2020-12-03160 citations
Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials.
2018-08-0161 citations
Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease.
2018-07-2528 citations
Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials
RMD Open2017-09-0128 citations

5 more papers not shown